Volume | 2,169,369 |
|
|||||
News | - | ||||||
Day High | 28.78 | Low High |
|||||
Day Low | 28.135 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Royalty Pharma PLC | RPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
28.66 | 28.135 | 28.78 | 28.41 | 28.76 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
24,681 | 2,169,369 | $ 28.35 | $ 61,506,247 | - | 25.92 - 35.76 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:31:05 | 1 | $ 28.50 | USD |
Royalty Pharma PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.97B | 597.43M | - | 2.35B | 1.13B | 1.90 | 14.95 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Royalty Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 28.00 | 28.99 | 27.68 | 28.24 | 3,290,121 | 0.41 | 1.46% |
1 Month | 28.67 | 29.73 | 27.21 | 28.35 | 2,888,709 | -0.26 | -0.91% |
3 Months | 28.68 | 31.655 | 27.21 | 29.49 | 2,839,991 | -0.27 | -0.94% |
6 Months | 27.85 | 31.655 | 26.07 | 28.79 | 2,648,920 | 0.56 | 2.01% |
1 Year | 35.29 | 35.76 | 25.92 | 29.48 | 2,481,427 | -6.88 | -19.50% |
3 Years | 44.18 | 47.10 | 25.92 | 36.01 | 2,132,870 | -15.77 | -35.69% |
5 Years | 45.90 | 57.50 | 25.92 | 38.20 | 2,141,438 | -17.49 | -38.10% |
Royalty Pharma Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |